atrophy

Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.

Promestriene (3-propyl ethyl) (INN) is a synthetic estrogen and glucocorticoid used topically in a 1% cream formulation. It is described as a tropic agent and antiseborrheic.

Branaplam (LMI 070) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.

MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity.

Dexamethasone is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory, immunosuppressive, and apoptosis-inducing activities. It inhibits the production of inflammatory miRNA-155 exosomes in macrophages, significantly reduces inflammatory cytokine expression in neutrophils and monocytes, suppresses LPS-induced macrophage inflammation, and induces autophagy. It is commonly used to induce animal models of depression, muscle atrophy, and hypertension, and holds potential in COVID-19 research.

Apitegromab (SRK-015) is a new myostatin inhibitor, an antibody targeting myostatin precursor, which can be used to study neuromuscular diseases including spinal muscular atrophy.

SMN-C3 (MV8T2MCK57) is an orally active modulator of SMN2 splicing, and has the potential to treat spinal muscular atrophy (SMA).

Epristeride (ONO-9302) is an orally active, selective and non-competitive steroidal 5-α-reductase isoform 2 inhibitor that inhibits SR isoform 2.Episteride reduces prostate size and improves symptoms in men with BPH.Episteride induces atrophy and apoptosis of the ventral prostate in rats.

Fispemifene (HM-101) is an estrogen receptor modulator (SERM) used to treat genitourinary syndromes and vaginal atrophy.

OT-551 HCl is an NF-Κb inhibitor, a disubstituted hydroxylamine with antioxidant properties can be used for the treatment of cataracts and age-related macular degeneration and geographic atrophy (GA).

SMN-C2 is a selective regulator of SMN2 gene splicing, a risdiplam analogue, a selective RNA-binding ligand that regulates pre-mRNA splicing and acts by binding to SMN2 pre-mRNA.SMN-C2 has the potential to be used in the study of spinal muscular atrophy (SMA).

Gadopentetate dimeglumine is used in magnetic resonance imaging (MRI) to allow blood vessels, organs and other non-bone tissues to be visualized more clearly.Gadopentetate dimeglumine induces atrophy of spermatogonia.

Sabinene is a natural product that has antifungal and anti-inflammatory properties

Caffeic acid 4-O-glucoside (Linocaffein), a glycosylation product of Caffeic acid, reverses Aβ25-35-induced axonal atrophy and induces axonal regeneration in mouse cortical neurons, and can be used in Alzheimer's disease research.

RG7800 (RO6885247) has the potential for spinal muscular atrophy treatment. RG7800 is an SMN2 splicing modifier.

Perthane is the diethyl derivative of common pesticide DDD. It may cause adrenocortical atrophy in humans,and also prevent the formation of spontaneous mammary carcinoma.

1,2,3,6,7,8-Hexachlorodibenzofuran (1,2,3,6,7,8-HxCDF) is a type of polychlorinated dibenzofuran (PCDF). It promotes the expression of aryl hydrocarbon hydroxylase (AHH) and ethoxyresorufin-O-deethylase (EROD) genes in H-4-II-E rat hepatoma cells with EC50 values of 1.47 and 1.24 nM, respectively. 1,2,3,6,7,8-HxCDF also reduces rat body weight, causes thymic atrophy, and induces the expression of cytochrome P450 (CYP) subtype CYP1A1 and 4-chlorobiphenyl hydroxylase genes with EC50 values of 3.2, 0.9, 0.35, and 0.21 µmol kg.

Androgen receptormodulator 3 is a selective modulator of the androgen receptor, applied in the study of muscle atrophy.

Flumethasone pivalate (Locorten) has antipruritic, anti-inflammatory, and vasoconstrictive properties and can be used in studies about adrenocortical suppression, cutaneous atrophy, plasma transcortin binding, and telangiectasia.

D153249 is a promoter of spinal muscular atrophy (SMA).

Rg3039 (PF-06687859) is a potent DcpS inhibitor. DcpS is a therapeutic target for spinal muscular atrophy. Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene which produces an essential protein known as SMN. RG3039 improves motor function in SMA mice. RG3039 also showed activity to improve survival, function and motor unit pathologies in two SMA mouse models.

Nicotinamide Riboside Triflate (SRT647 Triflate) is a natural NAD precursor that increases NAD levels, enhances oxidative metabolism and prevents obesity induced by a high-fat diet+, and can be used in studies of muscle atrophy.

SMN2-Stablizer-27 is a stablizer of survival of motor neuron 2 (SMN2), and a post-translationally stablizing SMN protein for the treatment of spinal muscular atrophy (SMA).

The Survival of Motor Neurons (SMN) protein participates in RNA splicing. Decreases in SMN, typically a consequence of defects in the smn1 gene, result in the death of motor neurons and lead to the neurodegenerative disease, spinal muscular atrophy (SMA). Cuspin-1 is a small molecule upregulator of SMN that has been shown in vitro to increase levels of SMN in SMA patient fibroblasts by 50% at 18 μM. Its mechanism of action is thought to involve increased phosphorylation of ERK to initiate Ras-Raf-MEK signaling, which results in an increased rate of SMN translation.